tradingkey.logo
tradingkey.logo
Search

Thermo Fisher Scientific Inc

TMO
Add to Watchlist
594.000USD
+13.860+2.39%
Close 08-07 16:00ETQuotes delayed by 15 min
219.63BMarket Cap
32.58P/E TTM
TradingKey Chart
Intraday
1m
30m
1h
D
W
M
D

Today

+2.39%

5 Days

+3.43%

1 Month

+16.44%

6 Months

+9.43%

Year to Date

+2.51%

1 Year

+28.93%

Key Figures
578.000Open
594.260High
2.21MVolume
32.58P/E TTM
21.78P/E Dynamic
1.760Dividend TTM
0.60%Turnover Ratio
580.020Prev. Close
574.768Low
738.22MTurnover
34.67P/E Static
4.17P/B
0.30%Div Yield TTM
6.47%ROA
643.99052wk High
1.22Volume Ratio
6.33BNet Profit
369.75MShares
18.2339EPS TTM
0.88Beta
13.52%ROE
385.46052wk Low
3.36%Amplitude
40.70%Gross Margin
219.63BMarket Cap
6.04Reward/Risk
1.61%Risk Rate

Thermo Fisher Scientific Inc Stock (TMO) Closed Up by 3.20% on Jul 28: Drivers Behind the Movement

• Thermo Fisher exceeded quarterly earnings estimates and raised full-year organic revenue guidance. • Increased pharmaceutical capital expenditure and demand for clinical services boosted the company's backlog. • Technical indicators suggest a buy signal with an average analyst price target of $634.52.

TradingKeyTue, Jul 28

Stryker Corp Stock (SYK) Moved Up by 3.15% on Jul 24: Facts Behind the Movement

• Stryker exceeded second-quarter earnings expectations driven by strong MedSurg and Neurotechnology segment performance. • Management raised full-year organic growth and earnings guidance following higher elective procedure volumes. • Analyst upgrades and increased institutional demand contributed to positive momentum in Stryker shares.

TradingKeyFri, Jul 24

Stryker Corp Stock (SYK) Closed Up by 3.21% on Jul 23: Drivers Behind the Movement

• Stryker’s second-quarter earnings exceeded analyst expectations with growth in MedSurg and Neurotechnology. • Management raised full-year earnings guidance citing strong demand and elective procedure recovery. • Analysts increased price targets following positive performance and consistent robotic technology market expansion.

TradingKeyThu, Jul 23

Danaher Corp Stock (DHR) Moved Up by 6.78% on Jul 23: What Signal Does It Send?

• Danaher’s quarterly earnings surpassed analyst expectations, driving a rise in the company’s stock price. • Bioprocessing demand has normalized, signaling a recovery in the company’s biotechnology and life sciences segments. • Management raised full-year earnings and revenue guidance, citing sustainable growth in core business units.

TradingKeyThu, Jul 23

Thermo Fisher Scientific Inc Stock (TMO) Moved Up by 9.89% on Jul 23: A Full Analysis

• Thermo Fisher Q2 2026 results exceeded expectations amid bioprocessing recovery and inventory normalization. • Management raised full-year earnings guidance following strong growth in clinical research and diagnostics. • Analysts issued multiple buy ratings with an average price target of $603.15.

TradingKeyThu, Jul 23

Unitedhealth Group Inc Stock (UNH) Moved Up by 3.02% on Jul 21: Drivers Behind the Movement

• UnitedHealth reported strong quarterly earnings driven by growth in its Optum health services segment. • Stable Medicare Advantage reimbursement rates have improved sentiment toward the managed care sector. • A resilient labor market and cooling inflation are supporting UnitedHealth's commercial insurance revenue.

TradingKeyTue, Jul 21

Thermo Fisher Scientific Inc's Score

-0.34vs previous score
Forecast8.25
Financial Health8.41
Technical4.17
Valuation Dimensions7.10
Institutional Confidence10.00
Risk Assessment9.72

Media Coverage

Coverage Level

49°C

Very Low
Very High
Positive

Analyst Rating

Strong Buy
Buy
Hold
Sell
Strong Sell
BuyCurrent Rating
638.059Target Price
+10.01%Upside Space
Current Rating2026-082026-072026-062026-052026-042026-032026-022026-01
Strong Buy1010101010888
Buy1515161718181617
Hold77433353
Sell00000000
Strong Sell00000000

Thermo Fisher Scientific Inc Technical Analysis

1m
5m
15m
30m
1h
2h
4h
D
W
M
1m
5m
15m
D

Technical Indicators

Strong buy

Summary

Buy

Moving Average

Strong buy

Financial Indicators

Currency: USD
Quarterly
Quarterly
Annual
Relevant data have not been disclosed by the company yet.
Currency: USD
Quarterly
Quarterly
Annual
Relevant data have not been disclosed by the company yet.

Earnings

Next reporting date
2026-07-23
Reporting Period
2026Q2
Earnings / Forecast
4.68/5.71
Revenue / Forecast
11.99B/11.70B

Thermo Fisher Scientific Inc Profile

SectorHealthcare Equipment & Supplies
Ticker SymbolTMO
Number of employees125000
CountryUnited States of America

Ownership

ShareholdersProportion
Vanguard Capital Management, LLC6.53%
BlackRock Institutional Trust Company, N.A.4.71%
State Street Investment Management (US)4.47%
Capital World Investors2.96%
Shareholder TypesProportion
Investment Advisor53.12%
Investment Advisor/Hedge Fund29.79%
Research Firm2.97%
Pension Fund2.82%

FAQs

What is the current price of Thermo Fisher Scientific Inc (TMO)?

The current price of Thermo Fisher Scientific Inc (TMO) is 594.00.

What is the symbol of Thermo Fisher Scientific Inc?

The ticker symbol of Thermo Fisher Scientific Inc is TMO.

What is the 52-week high of Thermo Fisher Scientific Inc?

The 52-week high of Thermo Fisher Scientific Inc is 643.99.

What is the 52-week low of Thermo Fisher Scientific Inc?

The 52-week low of Thermo Fisher Scientific Inc is 385.46.

What is the market capitalization of Thermo Fisher Scientific Inc?

The market capitalization of Thermo Fisher Scientific Inc is 219.63B.

Is Thermo Fisher Scientific Inc (TMO) currently rated as Buy, Hold, or Sell?

According to analysts, Thermo Fisher Scientific Inc (TMO) has an overall rating of Buy, with a price target of 638.06.

What is the Earnings Per Share (EPS TTM) of Thermo Fisher Scientific Inc (TMO)?

The Earnings Per Share (EPS TTM) of Thermo Fisher Scientific Inc (TMO) is 17.78.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.